NYU Dentistry Awarded NIH Grant to Investigate Oral Cancer Pain Treatment
The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH), has awarded two New York University (NYU) College of Dentistry clinical researchers a 5-year, $3,276,000 grant to test whether nonviral codelivery of DNA and RNA will safely alleviate oral cancer pain.
The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH), has awarded two New York University (NYU) College of Dentistry clinical researchers a 5-year, $3,276,000 grant to test whether nonviral codelivery of DNA and RNA will safely alleviate oral cancer pain.
Building off past studies, the researchers will use the new grant to test whether the combination of OPRM1 (mu opioid receptor gene) re-expression and F2RL1 (gene for protease-activated receptor-2, or PAR2) downregulation in cancer can go beyond reducing cancer pain to eliminate it.
Brian Schmidt, DDS, MD, PhD, a professor in the Department of Oral and Maxillofacial Surgery at NYU College of Dentistry, director of NYU’s Bluestone Center for Clinical Research and the NYU Oral Cancer Center, and Seiichi Yamano, DDS, PhD, DMD, MMSc, associate professor of prosthodontics, have collaborated on this work over the last decade. Their efforts have been supported by three previous NIH-funded grants, according to the college.
Read the full story at: nyu.edu
